JP2022546387A5 - - Google Patents
Info
- Publication number
- JP2022546387A5 JP2022546387A5 JP2022512876A JP2022512876A JP2022546387A5 JP 2022546387 A5 JP2022546387 A5 JP 2022546387A5 JP 2022512876 A JP2022512876 A JP 2022512876A JP 2022512876 A JP2022512876 A JP 2022512876A JP 2022546387 A5 JP2022546387 A5 JP 2022546387A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- icam1
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025026469A JP2025104351A (ja) | 2019-08-23 | 2025-02-21 | 細胞間接着分子１（ｉｃａｍ１）抗体薬物抱合体およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891170P | 2019-08-23 | 2019-08-23 | |
| US62/891,170 | 2019-08-23 | ||
| PCT/US2020/047300 WO2021041171A1 (en) | 2019-08-23 | 2020-08-21 | Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025026469A Division JP2025104351A (ja) | 2019-08-23 | 2025-02-21 | 細胞間接着分子１（ｉｃａｍ１）抗体薬物抱合体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546387A JP2022546387A (ja) | 2022-11-04 |
| JP2022546387A5 true JP2022546387A5 (enExample) | 2023-02-13 |
Family
ID=74684305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512876A Pending JP2022546387A (ja) | 2019-08-23 | 2020-08-21 | 細胞間接着分子１（ｉｃａｍ１）抗体薬物抱合体およびそれらの使用 |
| JP2025026469A Pending JP2025104351A (ja) | 2019-08-23 | 2025-02-21 | 細胞間接着分子１（ｉｃａｍ１）抗体薬物抱合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025026469A Pending JP2025104351A (ja) | 2019-08-23 | 2025-02-21 | 細胞間接着分子１（ｉｃａｍ１）抗体薬物抱合体およびそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220280653A1 (enExample) |
| EP (1) | EP4017532A4 (enExample) |
| JP (2) | JP2022546387A (enExample) |
| CN (1) | CN114929263A (enExample) |
| CA (1) | CA3151800A1 (enExample) |
| WO (1) | WO2021041171A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170173005A1 (en) | 2014-03-27 | 2017-06-22 | Research Foundation Of The City University Of New York | Method for detecting or treating triple negative breast cancer |
| US20240148888A1 (en) * | 2021-02-23 | 2024-05-09 | Children's Medical Center Corporation | Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof |
| CN116920112A (zh) * | 2022-03-30 | 2023-10-24 | 浙江省肿瘤医院 | Icam1或其编码基因在制备胃癌治疗或诊断产品中的用途 |
| CN115737835A (zh) * | 2022-11-16 | 2023-03-07 | 浙江省肿瘤医院 | 特异性结合icam1的物质在制备甲状腺癌治疗或诊断产品中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063479A2 (en) * | 2006-11-17 | 2008-05-29 | Fred Hutchinson Cancer Research Center | Pancreatic cancer biomarkers |
| JPWO2012002388A1 (ja) * | 2010-07-01 | 2013-08-29 | 国立大学法人信州大学 | センチネルリンパ節への薬物輸送剤 |
| CA2921982C (en) * | 2013-09-02 | 2020-08-25 | Hangzhou Dac Biotech Co., Ltd | Novel cytotoxic agents for conjugation of drugs to cell binding molecule |
| CA2920192A1 (en) * | 2013-09-27 | 2015-04-02 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
| JP6447933B2 (ja) * | 2014-02-21 | 2019-01-09 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療 |
| SI3204018T1 (sl) * | 2014-10-07 | 2021-11-30 | Immunomedics, Inc. | Neoadjuvantna uporaba konjugatov protitelo-zdravilo |
| WO2017139623A1 (en) * | 2016-02-10 | 2017-08-17 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
| AU2018333966B2 (en) * | 2017-09-18 | 2025-04-03 | Trustees Of Boston University | Methods for treating NETosis and neutrophil activation |
-
2020
- 2020-08-21 CA CA3151800A patent/CA3151800A1/en active Pending
- 2020-08-21 CN CN202080074153.4A patent/CN114929263A/zh active Pending
- 2020-08-21 US US17/637,305 patent/US20220280653A1/en active Pending
- 2020-08-21 EP EP20858937.4A patent/EP4017532A4/en active Pending
- 2020-08-21 WO PCT/US2020/047300 patent/WO2021041171A1/en not_active Ceased
- 2020-08-21 JP JP2022512876A patent/JP2022546387A/ja active Pending
-
2025
- 2025-02-21 JP JP2025026469A patent/JP2025104351A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chari et al. | Immunoconjugates containing novel maytansinoids: promising anticancer drugs | |
| Kovtun et al. | Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen | |
| Yurkovetskiy et al. | Dolaflexin: a novel antibody–drug conjugate platform featuring high drug loading and a controlled bystander effect | |
| Sapra et al. | Investigational antibody drug conjugates for solid tumors | |
| Jain et al. | Current ADC Linker Chemistry: Jain, Smith, Ghone and Tomczuk | |
| Jeffrey et al. | Dipeptide-based highly potent doxorubicin antibody conjugates | |
| Lambert et al. | Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: a review | |
| Ricart et al. | Technology insight: cytotoxic drug immunoconjugates for cancer therapy | |
| JP2025016545A5 (enExample) | ||
| JP2021516960A5 (enExample) | ||
| Chia | A patent review on FDA‐approved antibody‐drug conjugates, their linkers and drug payloads | |
| Jackson et al. | Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates: Jackson and Stover | |
| Doronina et al. | Development of potent monoclonal antibody auristatin conjugates for cancer therapy | |
| Walles et al. | ADME and safety aspects of non-cleavable linkers in drug discovery and development | |
| Bumbaca et al. | Pharmacokinetics of protein and peptide conjugates | |
| Stephan et al. | Challenges in developing bioanalytical assays for characterization of antibody–drug conjugates | |
| Govindan et al. | Designing immunoconjugates for cancer therapy | |
| Moore et al. | Effects of an unlabeled loading dose on tumor-specific uptake of a fluorescently labeled antibody for optical surgical navigation | |
| FI3930847T3 (fi) | Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä | |
| JP2024525624A5 (enExample) | ||
| MXPA05012259A (es) | Composicion de farmaco conjugado. | |
| Zhang et al. | Blood–brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion | |
| JP2020526584A5 (enExample) | ||
| JP2025183203A5 (enExample) | ||
| Ryan et al. | Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies |